GALT advances Belapectin to Phase III for MASH with portal hypertension
Belapectin showed reduction in new varices and favorable biomarker changes in MASH with cirrhosis and portal hypertension, with a strong safety profile. The Phase III protocol is aligned with FDA and submission is set for end of Q3.